Journal Watch · Clinical Cancer Research · 2026

Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcinoma: a multicenter, single-arm, phase II trial.

Furthermore, ctDNA status and TME analysis highlighted potential markers for guiding precision treatment.

Cheng K, Zhang C, Liu J et al.Clinical Cancer Research3 min readPharma relevance 75/100

DOI: 10.1158/1078-0432.ccr-26-1824PMID: 42886001Study type: randomised / controlled clinical trial

TL;DR

Furthermore, ctDNA status and TME analysis highlighted potential markers for guiding precision treatment.

Key findings

  • The combination treatment was well tolerated, and no treatment-related deaths or unexpected safety signals were observed.
  • Notably, patients with baseline ctDNA negativity achieved a better survival.
  • Moreover, tumor microenvironment (TME) analysis revealed that baseline fibroblast activation protein-positive cancer-associated fibroblast and T-cell proportions in tumor tissue correlated with clinical outcomes, with distinct spatial distribution and interaction tendencies observed among patients with different responses.<h4>Conclusion</h4>Overall, the ICSBR regimen demonstrated a promising survival benefit as first-line treatment for mPDAC.
  • Furthermore, ctDNA status and TME analysis highlighted potential markers for guiding precision treatment.

Numbers at a glance (from the abstract)

60%78.3%95%67.2%91.1%73.9%58.9%85.7%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

The primary endpoint was the 6-month progression-free survival (PFS) rate, with a predefined target of 60%.<h4>Result</h4>Forty-six patients received at least one dose of treatment. The 6-month PFS rate was 78.3% (95% CI, 67.2%-91.1%). The median PFS and overall survival (OS) were 8.5 months (95% CI, 7.3-12.0 months) and 14.0 months (95% CI, 12.0 months-not reached), respectively. The objective response rate was 73.9% (95% CI, 58.9%-85.7%).

Full abstract (original)

Background: <h4>Purpose</h4>The prognosis for metastatic pancreatic ductal adenocarcinoma (mPDAC) remains dismal. In this multicenter, single-arm, phase II study, we evaluated the combination of serplulimab, gemcitabine plus nab-paclitaxel, and radiotherapy (ICSBR regimen) as first-line treatment for mPDAC patients (ChiCTR2300073237).<h4>Methods</h4>Patients with mPDAC were enrolled in the first-line setting. The treatment regimen consisted of serplulimab and gemcitabine plus nab-paclitaxel administered in 21-day cycles, combined with stereotactic body radiotherapy directed at the primary or metastatic sites during cycle 2. Additionally, comprehensive biomarker analysis was conducted.

What they did: The primary endpoint was the 6-month progression-free survival (PFS) rate, with a predefined target of 60%.<h4>Result</h4>Forty-six patients received at least one dose of treatment. The 6-month PFS rate was 78.3% (95% CI, 67.2%-91.1%). The median PFS and overall survival (OS) were 8.5 months (95% CI, 7.3-12.0 months) and 14.0 months (95% CI, 12.0 months-not reached), respectively. The objective response rate was 73.9% (95% CI, 58.9%-85.7%).

Results & conclusions: The combination treatment was well tolerated, and no treatment-related deaths or unexpected safety signals were observed. Notably, patients with baseline ctDNA negativity achieved a better survival. Moreover, tumor microenvironment (TME) analysis revealed that baseline fibroblast activation protein-positive cancer-associated fibroblast and T-cell proportions in tumor tissue correlated with clinical outcomes, with distinct spatial distribution and interaction tendencies observed among patients with different responses.<h4>Conclusion</h4>Overall, the ICSBR regimen demonstrated a promising survival benefit as first-line treatment for mPDAC. Furthermore, ctDNA status and TME analysis highlighted potential markers for guiding precision treatment.

Abstract © the authors / Clinical Cancer Research (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1158/1078-0432.ccr-26-1824 · PubMed 42886001.

Why it matters for pharma & biotech

  • Relevant to Pharmacology & Drug Discovery teams tracking Clinical Cancer Research for new targets, mechanisms and biomarkers.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Clinical Cancer Research study find?

Furthermore, ctDNA status and TME analysis highlighted potential markers for guiding precision treatment.

What type of study is this?

It is a randomised / controlled clinical trial, published in Clinical Cancer Research in 2026. The primary endpoint was the 6-month progression-free survival (PFS) rate, with a predefined target of 60%.<h4>Result</h4>Forty-six patients received at least one dose of treatment.

Where can I read the original paper?

The original is at the publisher via DOI 10.1158/1078-0432.ccr-26-1824. PubMed ID: 42886001. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Cheng K, Zhang C, Liu J et al.. Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcinoma: a multicenter, single-arm, phase II trial.. Clinical Cancer Research (2026). DOI: 10.1158/1078-0432.ccr-26-1824.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/radiotherapy-combined-with-serplulimab-and-chemotherapy-as-first-line-tr-261824/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides